Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence.

Matthew J Hamilton

Journal: Immunology and allergy clinics of North America 2019;38(3):469-481

PMID: 30007464

Free Full Text on PubMed Central View on PubMed

Abstract

Patients who present with typical features of mast cell activation with laboratory confirmation and without evidence of a clonal mast cell disorder or other medical condition should be initiated on medical treatment to block mast cells and their mediators. If a major response is achieved, a diagnosis of nonclonal mast cell activation syndrome (NC-MCAS) is likely and treatment should be optimized, including management of any associated conditions. In this review, the latest evidence with regard to the diagnosis and treatment of NC-MCAS is presented.

Address: Division of Gastroenterology, Hepatology, and Endoscopy, Harvard Medical School, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. Electronic address: [email protected].

DOI: 10.1016/j.iac.2018.04.002

Link outs

Free resources

Full Text Sources:

Other Literature Sources:

https://scite.ai/reports/30007464

Subscription / membership required

Full Text Sources:

MeSH Terms: Amine Oxidase (Copper-Containing), Cell Degranulation, Clone Cells, Evidence-Based Medicine, Humans, Mast Cells, Mastocytosis, Prostaglandin Antagonists, Prostaglandins, Tryptases